Beyond Air(XAIR) Newsfilter·2025-04-09 20:05Core Insights - Beyond Air, Inc. has published a scientific article on the use of intermittent inhaled nitric oxide (iNO) for treating nontuberculous mycobacterial (NTM) lung infections, highlighting its potential as a novel anti-NTM agent [1][2][3] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to treat respiratory illnesses, neurological disorders, and solid tumors [7][8] - The company has received FDA approval and CE Mark for its LungFit® PH system, aimed at treating hypoxic respiratory failure in neonates [7][11] Clinical Study Details - The LungFit GO NTM Trial was a 12-week, multi-center, open-label clinical trial conducted in Australia, involving 15 adult subjects with chronic refractory NTM lung disease [3][4] - The trial demonstrated high compliance (>90%) with the treatment, and no serious adverse events were reported during the 12-week treatment or follow-up periods [4][5] Efficacy and Safety Findings - Key efficacy endpoints showed meaningful improvements in quality of life, particularly in respiratory symptoms and emotional functioning [5] - Trends in the reduction of microbial load were observed, with one subject achieving culture conversion during the follow-up phase [5] Future Directions - The company plans to further evaluate the efficacy of inhaled NO in larger pivotal studies, as the pilot study results support its potential value [2][3]